Physician profile
Anna M Priebe
NPI 1386765501
$15,373.41
in general payments reported to CMS, 2019-2025
29 companies · $783 in 2025
The $783 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,683 · 2020: $4,252 · 2021: $1,808 · 2022: $382 · 2023: $3,520 · 2024: $946 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284 · Consulting Fee: $1,713 · Education: $1,020 · Travel and Lodging: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.29 |
| Consulting Fee | $1,712.50 |
| Education | $1,019.77 |
| Travel and Lodging | $231.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,048.76 | 2019-2024 | Davinci Xi, Da Vinci Surgical System |
| Seagen INC. | $3,283.45 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,855.09 | 2023-2025 | Lynparza, Imjudo, Enhertu |
| Eisai INC. | $1,620.00 | 2021 | |
| Glaxosmithkline, LLC. | $695.49 | 2022-2025 | Zejula, Jemperli |
| Myriad Genetic Laboratories, INC. | $418.64 | 2021-2024 | Myrisk |
| Tempus Ai, INC | $302.77 | 2024-2025 | Xt Cdx |
| Aadi Bioscience, INC. | $188.98 | 2024 | Fyarro |
| Genmab U.S., INC. | $159.23 | 2022-2025 | Tivdak |
| Astellas Pharma US INC | $142.61 | 2024-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $132.06 | 2022-2025 | Libtayo |
| Abbvie INC. | $94.21 | 2019-2021 | |
| Incyte Corporation | $83.87 | 2023-2024 | Monjuvi, Jakafi |
| Tesaro, INC. | $50.81 | 2019 | |
| Merck Sharp & Dohme LLC | $48.63 | 2024-2025 | Lynparza, Keytruda, Welireg |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.70 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $24.97 | 2022 | |
| Avanos Medical | $24.70 | 2025 | Pnb and Accessories |
| Bayer Healthcare Pharmaceuticals INC. | $23.80 | 2025 | |
| Integra Lifesciences Corporation | $22.88 | 2023 | Duraseal Exact Spinal Sealant System, Codman Hakim, Codman Certas |
| Exelixis INC. | $21.92 | 2025 | Cabometyx |
| Mirati Therapeutics, INC. | $20.40 | 2023 | Krazati |
| Pfizer INC. | $18.80 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.69 | 2023 | |
| Janssen Biotech, INC. | $17.22 | 2025 | Rybrevant |
| Cardinal Health 414 LLC | $15.35 | 2024 | Kit For The Preparation of Lymphoseek (Technetium Tc 99m Tilmanocept) |
| Taiho Oncology, INC. | $12.38 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Priebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.